# Insulet Corporation – Consensus ‘buy’ rating and 59.4% Upside Potential

- Link: https://www.directorstalkinterviews.com/insulet-corporation-consensus-buy-rating-and-59.4-upside-potential/4121132380
- Published: 2023-11-09T14:30:34+00:00
- Author: Charlotte Edwards

**Insulet Corporation** with ticker code (PODD) now have 18 market analysts covering
the stock. The analyst consensus now points to a rating of ‘buy’. The target price
High/Low ranges between $360.00 and $162.00 calculating the mean target price we
have $257.94. Now with the previous closing price of $161.87 this indicates there
is a potential upside of 59.4%. The 50 day moving average now sits at $156.88 and
the 200 day moving average is $254.68. The company has a market capitalization of
10.82B. The current share price for the company is: $154.97 USD

 The potential market cap would be $17,241,962,245 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 90.1, revenue per share of $22.35
and a 2.36% return on assets.

Insulet Corporation is primarily engaged in the development, manufacture and sale
of its Omnipod System, a continuous insulin delivery system for people with insulin-
dependent diabetes. The Omnipod System includes the Omnipod Insulin Management System(
Classic Omnipod), the Omnipod DASH Insulin Management System (Omnipod DASH), and
the Omnipod 5 Automated Insulin Delivery System (Omnipod 5). The Omnipod System 
features a small, lightweight, self-adhesive disposable tubeless Omnipod device (
Pod) that the user fills with insulin and wears directly on the body for up to three
days at a time, which delivers personalized doses of insulin, and the Personal Diabetes
Manager (PDM) or Controller, a wireless, handheld device that programs the Pod with
the user’s personalized insulin-delivery instructions and wirelessly monitors the
Pod’s operation. The Company sells Pods to Amgen Inc. (Amgen) for use in the Neulasta
Onpro kit, a delivery system for Amgen’s Neulasta.

Share on: